John O. Miners

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations

Medicine, Genetics, Pharmacology +17

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni et al. · JAMA Oncology · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID

Verawan Uchaipichat, Peter I. Mackenzie, Xiao-Hui Guo et al. · Drug Metabolism and Disposition · 2004 · 334 citations

Life Sciences, Biochemistry, Pharmacology +14

Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

Wichittra Tassaneeyakul, Donald Birkett, M Veronese et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 317 citations

Medicine, Biochemistry, Pharmacology +17

Interindividual Variability in Acetaminophen Glucuronidation by Human Liver Microsomes: Identification of Relevant Acetaminophen UDP-Glucuronosyltransferase Isoforms

Michael H. Court, Su Duan, Lisa L. von Moltke et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 302 citations

Pharmacy, Biochemistry, Pharmacology +16